Vita Life Sciences Limited (VLS) AI Stock Analysis

• Market Cap: AU$154.58M
• Dividend Yield: 4.33%
• Average Volume (3M): 14.76K
• Price to Earnings (P/E): 17.1
• Beta (1Y): 0.10
• Revenue Growth: 8.46%
• EPS Growth: -1.95%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.09
• Shares Outstanding: 54,620,354
• 10 Day Avg. Volume: 12,408
• 30 Day Avg. Volume: 14,758
• PEG Ratio: -2.13
• Price to Book (P/B): 2.10
• Price to Sales (P/S): 1.38
• P/FCF Ratio: 18.47
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 76 Outperform
• Price Target: AU$2.50 ▼(-0.79% Downside)

Vita Life Sciences Limited scores well due to its strong financial performance and reasonable valuation. The technical analysis supports a positive trend, although indicators suggest caution due to potential overbought conditions. The absence of earnings call and corporate events data does not impact the overall score.

Positive Factors

Strong recent revenue growth and margins

A 74.3% revenue surge alongside healthy gross and net margins indicates durable product-market fit and effective cost controls. Sustained top-line growth with margins provides capacity to reinvest in R&D, expand distribution and scale fixed costs, improving long-term profitability.

Conservative balance sheet with low leverage

Very low debt levels and a strong equity ratio give the company financial flexibility to fund organic growth, pursue strategic partnerships or acquisitions, and absorb economic downturns without material refinancing risk, supporting long-term resilience.

Multi-channel distribution strategy

A diversified sales model—direct, retail partnerships and e-commerce—reduces revenue concentration risk and captures secular shifts toward online health purchases. This structural channel mix supports durable customer reach, stable revenue mix and scalable go-to-market execution.

Negative Factors

Decline in free cash flow growth

Falling free cash flow growth can limit the firm's ability to fund capital expenditures, marketing and product development from internal resources. Over time this may force external financing, slow expansion, or constrain shareholder returns despite strong accounting profits.

Pressure on operating and net margins

Erosion in EBIT and net margins implies rising costs or pricing pressure may be outpacing revenue gains. If persistent, margin compression will reduce free cash generation and returns on invested capital, hindering reinvestment and weakening long-term competitive positioning.

Negative EPS growth

Negative EPS growth indicates the company’s earnings power has weakened relative to prior periods. Persistent EPS decline can signal operational challenges or dilution, undermining internal funding for growth initiatives and weakening confidence in sustained profit expansion.

Vita Life Sciences Limited Business Overview & Revenue Model

Company Description

Vita Life Sciences Limited (VLS) is a health and wellness company that specializes in the development and distribution of nutritional supplements and dietary products. The company operates primarily in the consumer health sector, focusing on providing high-quality vitamins, minerals, and herbal supplements. VLS aims to enhance the well-being of its customers through its innovative product offerings, which cater to various health needs and promote a balanced lifestyle.

How the Company Makes Money

Vita Life Sciences Limited generates revenue through the sale of its range of nutritional supplements and health products, which are marketed to both consumers and healthcare professionals. The company employs a multi-channel distribution strategy, including direct sales, partnerships with retailers, and e-commerce platforms, allowing it to reach a broad audience. Key revenue streams include product sales, online orders, and collaborations with health practitioners who recommend VLS products. Additionally, VLS may benefit from strategic partnerships with other health and wellness brands, enhancing its market presence and sales potential.

Vita Life Sciences Limited Financial Statement Overview

Summary

Vita Life Sciences Limited shows strong financial health with impressive revenue growth and profitability metrics. The balance sheet is robust with low leverage, enhancing financial stability. However, the decline in free cash flow growth and slight pressure on profit margins warrant attention.

Income Statement

Vita Life Sciences Limited has demonstrated strong revenue growth over the years, with a notable increase of 74.3% in the latest year. The company maintains healthy gross and net profit margins, indicating efficient cost management and profitability. EBIT and EBITDA margins are also robust, reflecting strong operational performance. However, a slight decline in EBIT and net profit margins in the most recent year suggests potential pressure on profitability.

Balance Sheet

The company's balance sheet is solid, with a very low debt-to-equity ratio, indicating minimal leverage and financial risk. The equity ratio is strong, showing a high proportion of assets financed by equity. Return on equity remains healthy, although it has decreased slightly, suggesting a need for improved efficiency in generating profits from shareholders' equity.

Cash Flow

Cash flow analysis reveals a decline in free cash flow growth, which could impact future investment capacity. The operating cash flow to net income ratio is moderate, indicating that cash generation from operations is not fully aligned with net income. However, the free cash flow to net income ratio remains high, suggesting that the company efficiently converts its earnings into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	85.60M	79.50M	74.16M	66.89M	57.10M	46.48M
Gross Profit	51.65M	47.24M	42.60M	39.74M	34.81M	29.27M
EBITDA	12.83M	13.46M	13.10M	11.37M	11.71M	8.88M
Net Income	9.33M	8.78M	9.08M	7.08M	8.29M	6.09M
Balance Sheet
Total Assets	74.64M	71.89M	59.81M	51.80M	45.27M	39.10M
Cash, Cash Equivalents and Short-Term Investments	29.40M	28.60M	24.63M	15.69M	15.89M	14.48M
Total Debt	2.25M	517.00K	387.00K	601.00K	373.00K	2.07M
Total Liabilities	22.03M	19.61M	16.48M	15.30M	14.85M	14.66M
Stockholders Equity	52.71M	52.35M	43.40M	36.57M	30.75M	24.72M
Cash Flow
Free Cash Flow	9.17M	5.96M	12.32M	7.54M	5.73M	7.46M
Operating Cash Flow	10.09M	6.16M	12.98M	7.68M	5.89M	7.54M
Investing Cash Flow	-920.00K	-198.00K	-660.00K	-139.00K	-155.00K	-89.00K
Financing Cash Flow	-8.56M	-2.99M	-2.88M	-3.10M	-4.39M	-3.03M

Vita Life Sciences Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.52
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:VLS, the sentiment is Positive. The current price of 2.52 is below the 20-day moving average (MA) of 2.64, below the 50-day MA of 2.55, and above the 200-day MA of 2.28, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 54.47 is Neutral, neither overbought nor oversold. The STOCH value of 72.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:VLS.

Vita Life Sciences Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VLS	76 Outperform	AU$154.58M	17.10	18.35%	4.33%	8.46%	-1.95%
VIT	59 Neutral	AU$37.78M	10.56	7.64%	3.28%	0.13%	-12.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MVP	46 Neutral	AU$54.64M	460.00	0.19%	―	17.82%	―
IDT	37 Underperform	AU$19.33M	-2.58	-35.58%	―	45.30%	-24.18%

Vita Life Sciences Limited Corporate Events

Vita Life Sciences Cancels 18,584 Shares Under On‑Market Buy-Back

Vita Life Sciences Limited has cancelled 18,584 ordinary fully paid shares on 19 December 2025 as part of an on-market share buy-back program, according to its latest capital notification. The reduction in issued capital forms part of the company’s ongoing capital management strategy and marginally increases the ownership percentage of remaining shareholders, signalling continued efforts to optimise its balance sheet and potentially enhance shareholder value.

The most recent analyst rating on (AU:VLS) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.

Vita Life Sciences Projects Strong FY2025 Growth Amid Market Expansion

Vita Life Sciences has issued its FY2025 guidance, projecting significant sales growth to $91m-$92m, up from $79.5m in FY2024, and a pre-tax profit increase to $13.2m-$13.7m. The growth is driven by robust performance in Malaysia and Singapore, with anticipated 30% revenue growth, and steady contributions from the Australian market. However, export sales to China are expected to fall short of initial expectations due to trade partner transitions. The company is committed to investing in brand development and market positioning to support long-term growth, focusing on core markets and exploring new opportunities in Vietnam and China.

The most recent analyst rating on (AU:VLS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.

Vita Life Sciences Updates on Share Buy-Back Program

Vita Life Sciences Limited has announced an update on its ongoing share buy-back program. The company reported that it bought back 18,584 ordinary fully paid securities on the previous day, adding to a total of 541,740 securities repurchased prior to that day. This buy-back initiative is part of Vita Life Sciences’ strategy to manage its capital structure and potentially enhance shareholder value.

The most recent analyst rating on (AU:VLS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.

Vita Life Sciences Announces Cessation of Securities Through Buy-Back

Vita Life Sciences Limited announced the cessation of 3,062 ordinary fully paid securities due to an on-market buy-back, effective December 10, 2025. This move could potentially impact the company’s capital structure and market perception, as buy-backs are often seen as a signal of management’s confidence in the company’s future prospects.

The most recent analyst rating on (AU:VLS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.

Vita Life Sciences Announces Cessation of Securities

Vita Life Sciences Limited announced the cessation of 104,392 ordinary fully paid securities as part of an on-market buy-back, effective November 24, 2025. This move is likely to impact the company’s capital structure and could influence its market positioning by potentially increasing shareholder value through a reduction in outstanding shares.

The most recent analyst rating on (AU:VLS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.

Vita Life Sciences Updates on Share Buy-Back Progress

Vita Life Sciences Limited has announced an update on its ongoing share buy-back program, reporting the purchase of 31,265 ordinary fully paid securities on the previous day, adding to a total of 507,413 securities bought back to date. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value, reflecting a proactive approach to managing its financial resources.

The most recent analyst rating on (AU:VLS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.

Vita Life Sciences Updates on Securities Buy-Back Program

Vita Life Sciences Limited has announced an update regarding its ongoing on-market buy-back program, with a total of 29,959 ordinary fully paid securities bought back on the previous day, adding to the cumulative total of 477,454 securities repurchased before that day. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value.

The most recent analyst rating on (AU:VLS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.

Vita Life Sciences Updates on Securities Buy-Back

Vita Life Sciences Limited has announced a daily update on their ongoing on-market buy-back of ordinary fully paid securities. As of November 6, 2025, the company has bought back a total of 434,286 securities, with an additional 4,954 securities purchased on the previous day. This buy-back strategy indicates the company’s efforts to optimize its capital structure and potentially enhance shareholder value.

The most recent analyst rating on (AU:VLS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.

Vita Life Sciences Announces Cessation of Securities via Buy-Back

Vita Life Sciences Limited announced the cessation of 226,873 of its ordinary fully paid securities due to an on-market buy-back, effective November 5, 2025. This move is part of the company’s capital management strategy, potentially impacting its market positioning by reducing the number of shares in circulation, which could influence shareholder value and market perception.

The most recent analyst rating on (AU:VLS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.